DUX4 and facioscapulohumeral muscular dystrophy: Nelson Hsia (Dyne Therapeutics) described a strategy to deliver the DUX4-targeting PMO FM10 to FSHD myotubes by coupling the therapeutic oligonucleotide to a TfR antibody Fab fragment.